COVID AND CHANGES IN BLOOD CLOTTING
Keywords:
COVID-19, coagulation, thrombosis, blood clotting, D-dimer, endothelial dysfunction, hypercoagulability, cytokine storm.Abstract
This article explores the relationship between COVID-19 infection and alterations in blood clotting mechanisms. Since the onset of the pandemic, clinical evidence has demonstrated that COVID-19 is not only a respiratory disease but also a systemic condition with significant hematological complications. Patients with severe forms of COVID-19 frequently exhibit abnormalities in coagulation, including increased risk of venous thromboembolism, disseminated intravascular coagulation (DIC), and microthrombi in vital organs. The article examines the underlying pathophysiological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic strategies related to coagulation disorders in COVID-19. Particular attention is given to the role of endothelial dysfunction, hyperinflammatory response, and cytokine storm in promoting a hypercoagulable state.
Downloads
References
1. Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18(4), 844–847.
2. Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135(23), 2033–2040.
3. Iba, T., Levy, J. H., Levi, M., & Thachil, J. (2020). Coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 18(9), 2103–2109.
4. Ackermann, M., Verleden, S. E., Kuehnel, M., et al. (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. New England Journal of Medicine, 383, 120–128.
5. World Health Organization (2021). Clinical management of COVID-19: Living guidance. Geneva: WHO Press.
